65 and older, any sex, with Obesity or Aging. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Body Composition as Total Fat Mass/ Total Fat-free Mass RatioPrimary· 16 weeks
total fat mass/total fat-free mass ratio reported as arbitrary units (ratio), calculated by dividing total fat mass by total fat-free mass (lean mass) at baseline and at 16 weeks in both groups. Primary measurements of fat and fat-free mass is done using DEXA
Baseline
Group
Value
95% CI
Semaglutide
1.04
± 0.07
Standard of Care Only
1.0
± 0.07
16 Weeks
Group
Value
95% CI
Semaglutide
0.96
± 0.06
Standard of Care Only
0.99
± 0.07
Body WeightPrimary· 16 weeks
body weight reported in Kg at at baseline and at 16 weeks in both groups
Baseline
Group
Value
95% CI
Semaglutide
107.8
± 7.7
Standard of Care Only
100.0
± 6.7
16 weeks
Group
Value
95% CI
Semaglutide
99.7
± 7.2
Standard of Care Only
97.1
± 7.5
Total Fat MassSecondary· 16 weeks
total fat mass reported in Kg and measured using DEXA at baseline and at 16 weeks in both groups
Baseline
Group
Value
95% CI
Semaglutide
52.1
± 3.6
Standard of Care Only
47.8
± 3.9
16 weeks
Group
Value
95% CI
Semaglutide
46.8
± 3.6
Standard of Care Only
46.3
± 4.1
Total Fat-free Mass (Lean Mass)Secondary· 16 weeks
total fat-free mass (lean mass) reported in Kg and measured using DEXA at baseline and at 16 weeks in both groups
baseline
Group
Value
95% CI
Semaglutide
51.0
± 4.2
Standard of Care Only
47.8
± 2.2
16 weeks
Group
Value
95% CI
Semaglutide
49.5
± 4.0
Standard of Care Only
47.0
± 2.4
Adverse events — posted to ClinicalTrials.gov
Time frame: 16 weeks.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly obese subjects on body weight and body composition as assessed by DEXA.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT06908694 — Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
· Phase 4
· recruiting
NCT06852391 — JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide i
· Phase 4
· recruiting
NCT05746039 — Feasibility of Semaglutide in Advanced Lung Disease
· Phase 1, PHASE2
· recruiting
Other recruiting trials for Obesity
Currently open trials in the same condition.
NCT07403604 — Effect of Insulin Lowering on Lipogenesis
· Phase 1
· recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee
· Phase 3
· recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
· recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart
· Phase 3
· recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl
· Phase 1
· recruiting
Other State University of New York at Buffalo trials
Trials by the same sponsor.
NCT07072767 — Hybrid Dissemination Study of A Digital-Analog Intervention to Increase Live Donor Kidney Transplantation
· NA
· not yet recruiting
NCT07140848 — CGM-Enhanced DPP to Prevent Type 2 Diabetes in Adults With Prediabetes
· NA
· not yet recruiting
NCT07433959 — Neuromodulation to Improve Grasping Function After SCI
· NA
· not yet recruiting
NCT07403539 — Speech Learning and Speech Production in Parkinson's Disease
· NA
· recruiting
NCT05367362 — Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute
· Phase 2
· withdrawn
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by State University of New York at Buffalo
Last refreshed: 17 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05302596.